[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-461543-105":59,"doc-detail-461543-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","temporal-trends-and-outcomes-of-amyloidosis-in-korea-a-14-year-nationwide-cohort-study","Temporal Trends and Outcomes of Amyloidosis in Korea - A 14-Year Nationwide Cohort Study","","Evaluates how amyloidosis incidence, prevalence, and outcomes have changed over time in Korea, emphasizing the prognostic impact of cardiac involvement in the modern treatment era. Using the Korean National Health Insurance Service database, the study analyzes 5165 newly diagnosed patients, defining cardiac involvement by clinical and device criteria and applying propensity score matching to compare mortality risks. Results show rising disease burden after 2019 and persistently high cardiovascular mortality despite improving all-cause survival.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/temporal-trends-and-outcomes-of-amyloidosis-in-korea-a-14-year-nationwide-cohort-study/461543/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/temporal-trends-and-outcomes-of-amyloidosis-in-korea-a-14-year-nationwide-cohort-study/461543.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-02","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What time periods were analyzed for trends in amyloidosis outcomes?","Question",{"text":112,"@type":113},"Outcomes were analyzed across three periods: 2009–2013, 2014–2018, and 2019–2022.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study define cardiac involvement in amyloidosis patients?",{"text":117,"@type":113},"Cardiac involvement was defined by the presence of heart failure, cardiomyopathy, atrial fibrillation, or pacemaker implantation.",{"name":119,"@type":110,"acceptedAnswer":120},"What was the association between cardiac involvement and mortality?",{"text":121,"@type":113},"In the matched cohort, cardiac involvement was linked to higher all-cause death (HR 1.396) and higher cardiovascular death (HR 1.879).",{"name":123,"@type":110,"acceptedAnswer":124},"What key outcome pattern did the authors observe over the study period?",{"text":125,"@type":113},"All-cause mortality gradually declined, but cardiovascular mortality showed no significant improvement and remained persistently high in the most recent period.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},461543,1790916541,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article  \nTemporal Trends and Outcomes of Amyloidosis in Korea: A 14-Year Nationwide Cohort Study  \nMi-Hyang Jung 1,2, Hae Ok Jung 1,2, *, So-Young Lee 1,2, Jong-Chan Youn 1,2, Yeo Reum Kim 1,2, Hoseob Kim 3 and Woo-Baek Chung 1,2  \nReceived: 7 December 2025  \nRevised: 26 December 2025  \nAccepted: 30 December 2025  \nPublished: 31 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea  \n2 Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea  \n3 Data Science Team, Hanmi Pharm. Co., Ltd., Seoul 05545, Republic of Korea  \n* [Correspondence: hojheart@gmail.com or hojheart@catholic.ac.kr](Correspondence: hojheart@gmail.com or hojheart@catholic.ac.kr); Tel.: +82-2-2258-1128  \nAbstract  \nBackground/Objectives: The diagnostic and therapeutic landscape of amyloidosis has evolved significantly with the introduction of non-invasive imaging and novel agents. However, contemporary real-world data reflecting these recent changes—particularly regarding the burden and prognostic impact of cardiac involvement—remain limited. We aimed to evaluate up-to-date temporal trends in the incidence, prevalence, and outcomes of amyloidosis using a nationwide cohort spanning the recent era. Methods: Using the Korean National Health Insurance Service database, we identified 5165 patients with newly diagnosed amyloidosis. Cardiac amyloidosis was defined by the presence of heart failure, cardiomyopathy, atrial fibrillation, or pacemaker implantation. Propensity score matching was performed to compare mortality risks between patients with and without cardiac involvement. Temporal trends in outcomes were analyzed across three periods (2009–2013, 2014–2018, and 2019–2022) . Results: The incidence and prevalence of amyloidosis steadily increased, with a marked rise observed after 2019 . Cardiac involvement was identified in 44.6% of patients and was associated with significantly higher risks of all-cause death (hazard ratio [HR] 1.396; 95% CI 1.214–1.606) and cardiovascular death (HR 1.879; 95% CI 1.254–2.816) in the matched cohort. Notably, while all-cause mortality gradually declined over the study period, cardiovascular mortality showed no significant improvement, remaining persistently high even in the most recent cohort. Conclusions: In this contemporary nationwide cohort, the burden of amyloidosis has grown over the past decade. Despite improvements in overall survival, the persistent risk of cardiovascular mortality highlights a critical unmet need for targeted cardiovascular management in this population.  \nKeywords: amyloidosis; epidemiology; outcome assessment; health care; mortality  \n1. Introduction  \nAmyloidosis is a rare disease characterized by the deposition of amyloid fibrils in multiple organs, leading to progressive dysfunction [1–3] . It encompasses a heterogenous group of disorders, most notably light-chain (AL) and transthyretin (ATTR) amyloidosis, which differ significantly in pathophysiology and prognosis [2] . Despite increasing awareness of its clinical implications, amyloidosis remains underdiagnosed, often identified only at advanced stages due to limited recognition and nonspecific symptoms [2,3] . However,  \nthe landscape of amyloidosis management is rapidly evolving. Recent advancements have been pivotal across subtypes: for AL amyloidosis, the introduction of anti-CD38 monoclonal antibodies (e.g., daratumumab) has dramatically improved hematologic response and survival [2,4] . Concurrently, for ATTR amyloidosis, the widespread adoption of noninvasive imaging modalities (e.g., bone scintigraphy) and t","cbCaistE2uoPxHkO","https://ap.wps.com/l/cbCaistE2uoPxHkO","pdf",3010795,13,"English","# Abstract\n## Background/Objectives\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What time periods were analyzed for trends in amyloidosis outcomes?\",\"answer\":\"Outcomes were analyzed across three periods: 2009–2013, 2014–2018, and 2019–2022.\"},{\"question\":\"How did the study define cardiac involvement in amyloidosis patients?\",\"answer\":\"Cardiac involvement was defined by the presence of heart failure, cardiomyopathy, atrial fibrillation, or pacemaker implantation.\"},{\"question\":\"What was the association between cardiac involvement and mortality?\",\"answer\":\"In the matched cohort, cardiac involvement was linked to higher all-cause death (HR 1.396) and higher cardiovascular death (HR 1.879).\"},{\"question\":\"What key outcome pattern did the authors observe over the study period?\",\"answer\":\"All-cause mortality gradually declined, but cardiovascular mortality showed no significant improvement and remained persistently high in the most recent period.\"}]","Temporal Trends and Outcomes of Amyloidosis in Korea - A 14-Year Nationwide Cohort Study | PDF",1790761838,33]